🔥🐔 BizChicken 🐔🔥
Companies Similar to Biomea Fusion, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
BioAtla, Inc.
BA3011
Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.
Symbol: BCAB
Recent Price: $0.59
Industry: Biotechnology
CEO: Dr. Jay M. Short Ph.D.
Sector: Healthcare
Employees: 65
Address: 11085 Torreyana Road, San Diego, CA 92121
Phone: 858 558 0708
Last updated: 2024-12-31
Molecular Templates, Inc.
ETB Drug Platform
Molecular Templates, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
Symbol: MTEM
Recent Price: $0.05
Industry: Biotechnology
CEO: Dr. Eric E. Poma Ph.D.
Sector: Healthcare
Employees: 62
Address: 9301 Amberglen Boulevard, Austin, TX 78729
Phone: 512 869 1555
Leadership
- Eric Poma, Ph.D., Chief Executive Officer & Chief Scientific Officer
- Jason Kim, President & Chief Financial Officer
- Kristen Quigley, Chief Operating Officer
- Grace Kim, Chief Strategy Officer & Head of Investor Relations
- Michelle Iwamoto-Fan, Ph.D., J.D., Senior Vice President and General Counsel
- Chris Moore, Ph.D., Senior Vice President and Head of Preclinical Development and Translational Medicine
- Joseph Phillips, Ph.D., Senior Vice President and Head of CMC Development
- Harold E. “Barry” Selick, Ph.D., Chairman of the Board
- David R. Hoffmann, Director
- Kevin M. Lalande, Founding Managing Director and Chief Investment Officer of Santé
- Gabriela Gruia, M.D., Director
- Corsee Sanders, Ph.D., Director
Last updated: 2024-12-31
Passage Bio, Inc.
PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06
Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.
Symbol: PASG
Recent Price: $0.67
Industry: Biotechnology
CEO: Dr. William Chou M.D.
Sector: Healthcare
Employees: 58
Address: One Commerce Square, Philadelphia, PA 19103
Phone: 267 866 0311
Leadership
- William Chou, MD, President and Chief Executive Officer
- Kathleen Borthwick, Chief Financial Officer
- Sue Browne, PhD, Chief Scientific Officer
- Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
- Eden Fucci, SVP Technical Operations
- Stuart Henderson, Chief Business Officer
- Karl Whitney, PhD, SVP Global Regulatory Affairs
- James M. Wilson, MD, PhD, Scientific Advisor
- Maxine Gowen, PhD, Chairwoman
- Athena Countouriotis, MD,
- Derrell D. Porter, MD,
- Dolan Sondhi, PhD,
- Sandip Kapadia,
- Tom Kassberg,
- Saqib Islam,
- Samiah Al-Zaidy, MD, Vice President, Clinical Development
- Andrea Campanile, Vice President, Clinical Operations
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
89bio, Inc.
pegozafermin
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.
Symbol: ETNB
Recent Price: $7.87
Industry: Biotechnology
CEO: Mr. Rohan Palekar
Sector: Healthcare
Employees: 70
Address: 142 Sansome Street, San Francisco, CA 94104
Phone: 415 432 9270
Last updated: 2024-12-31
Biomea Fusion, Inc.
BMF-219
Biomea Fusion, Inc. is a biopharmaceutical company specializing in the discovery and development of covalent small molecule drugs for patients with genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, targets multiple cancers.
Symbol: BMEA
Recent Price: $3.88
Industry: Biotechnology
CEO: Mr. Thomas Andrew Butler
Sector: Healthcare
Employees: 107
Address: 900 Middlefield Road, Redwood City, CA 94063
Phone: 650 980 9099
Last updated: 2024-12-31
Biomerica, Inc.
diagnostic and therapeutic products
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for medical conditions and diseases worldwide, focusing on gastrointestinal diseases, food intolerances, and diabetes.
About | About | Contact | Contact | About | News | News | About | About | About | About | About
Symbol: BMRA
Recent Price: $0.31
Industry: Medical - Devices
CEO: Mr. Zackary S. Irani
Sector: Healthcare
Employees: 64
Address: 17571 Von Karman Avenue, Irvine, CA 92614
Phone: 949 645 2111
Last updated: 2024-12-31
Biotricity, Inc.
Bioflux
Biotricity, Inc. is a medical technology company that provides biometric data monitoring solutions, focusing on remote monitoring solutions for medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions.
About | About | Contact | Contact | About | About | ESG | About | DEI | About | About | About | About | About | About
Symbol: BTCY
Recent Price: $0.25
Industry: Medical - Devices
CEO: Dr. Waqaas Al-Siddiq Ph.D.
Sector: Healthcare
Employees: 55
Address: 275 Shoreline Drive, Redwood City, CA 94065
Phone: 650 832 1626
Last updated: 2024-12-31
Day One Biopharmaceuticals, Inc.
DAY101
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for genetically defined cancers. Their lead product candidate is DAY101, currently in Phase II clinical trials for pediatric patients with low-grade glioma.
Vision/Values | Leadership | About | Contact | About | Leadership | Leadership | Leadership | Leadership | Leadership | About | About
Symbol: DAWN
Recent Price: $12.58
Industry: Biotechnology
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
Sector: Healthcare
Employees: 174
Address: 395 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 484 0899
Leadership
- Samuel Blackman, MD, PhD, Head of R&D
- Elly Barry, MD, Chief Medical Officer
- Jeremy Bender, PhD, MBA, Director
- Davy Chiodin, PharmD, Chief Development Officer
- Adam Dubow, General Counsel
- Lauren Merendino, MBA, Chief Commercial Officer
- John Stubenrauch, Chief Technology Officer
- Jaa Roberson, Chief People Officer
- Charles N. York II, MBA, Chief Operating and Financial Officer
- Garry Nicholson, MBA, Chair
- Habib Dable, Director
- Scott Garland, Director
- Michael Gladstone, Director
- William Grossman, MD, PhD, Director
- Natalie Holles, Director
- John A. Josey, PhD, MBA, Director
- Saira Ramasastry, MS, MPhil, Director
Last updated: 2024-12-31
Fortress Biotech, Inc.
Pharmaceutical and Biotechnology Products
Fortress Biotech, Inc., is a biopharmaceutical company focused on developing and commercializing a range of dermatology products and late-stage product candidates for various medical conditions.
About | About | About | Leadership | Directors | About | About | Contact | Careers | Careers | Careers | About | About | About
Symbol: FBIO
Recent Price: $2.18
Industry: Biotechnology
CEO: Dr. Lindsay Allan Rosenwald
Sector: Healthcare
Employees: 186
Address: 1111 Kane Concourse, Bay Harbor Islands, FL 33154
Phone: 781 652 4500
Leadership
- Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer
- Michael S. Weiss, Executive Vice Chairman, Strategic Development
- David Jin, Chief Financial Officer and Head of Corporate Development
- George Avgerinos, Ph.D., Senior Vice President, Biologics Operations
- Samuel Berry, General Counsel and Corporate Secretary
- Jimmie Harvey, Jr., M.D., Director
- Malcolm Hoenlein, Director
- Dov Klein, Director
- J. Jay Lobell, Director
- Kevin L. Lorenz, J.D., Director
- Lucy Lu, M.D., Director
Last updated: 2024-12-31
Gossamer Bio, Inc.
GB002, GB004, GB5121, GB7208
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.
About | About | Management | Directors | Contact | Locations | Contact | Contact | About | About
Symbol: GOSS
Recent Price: $0.88
Industry: Biotechnology
CEO: Mr. Faheem Hasnain
Sector: Healthcare
Employees: 135
Address: 3013 Science Park Road, San Diego, CA 92121
Phone: 858 684 1300
Leadership
- Faheem Hasnain, Chairman
- Richard Aranda, M.D., Chief Medical Officer
- Jeff Boerneke, General Counsel and Secretary
- Matt Cravets, Senior Vice President, Biometrics
- Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
- Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
- Caryn Peterson, Executive Vice President, Regulatory Affairs
- Bob Smith, Chief Commercial Officer
- Christian Waage, Executive Vice President, Technical Operations & Administration
- Deanna Weber, Senior Vice President, Human Resources
- Russell J. Cox, Director
- Thomas Daniel, Director
- Skye Drynan, Director
- Sandra Milligan, Director
- Steven D. Nathan, Director
- John Quisel, Director
Last updated: 2024-12-31
Ocean Biomedical, Inc.
Humanized Monoclonal Antibodies, Small Molecule Candidates, Malaria Vaccine
Ocean Biomedical, Inc. is a biopharmaceutical company that develops therapeutic products for oncology, fibrosis, infectious diseases, and inflammation, with a focus on innovative treatments like monoclonal antibodies targeting Chi3l1 and small molecules targeting Chit1.
Symbol: OCEA
Recent Price: $0.60
Industry: Biotechnology
CEO: Dr. Jack A. Elias M.D.
Sector: Healthcare
Employees: 9
Address: Room 325, 55 Claverick Street, Providence, RI 02903
Phone: 401-444-7375
Last updated: 2024-12-31
Pliant Therapeutics, Inc.
PLN-74809
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.
Symbol: PLRX
Recent Price: $12.79
Industry: Biotechnology
CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector: Healthcare
Employees: 166
Address: 260 Littlefield Avenue, South San Francisco, CA 94080
Phone: 650 481 6770
Last updated: 2024-12-31
Sana Biotechnology, Inc.
N/A
Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines, developing cell engineering platforms for various therapeutic areas including oncology, diabetes, and genetic disorders.
Symbol: SANA
Recent Price: $1.61
Industry: Biotechnology
CEO: Dr. Steven D. Harr M.D.
Sector: Healthcare
Employees: 328
Address: 188 East Blaine Street, Seattle, WA 98102
Phone: 206 701 7914
Last updated: 2024-12-31
Sutro Biopharma, Inc.
Xpress CF+
Sutro Biopharma, Inc. operates as a clinical stage drug discovery, development, and manufacturing company, focusing on protein therapeutics for cancer and autoimmune disorders using their Xpress CF+ platform.
About | About | News | About | Leadership | Leadership | About | About | About | Contact | About | About | About | Careers | Leadership | About | Leadership | Leadership | Leadership | About | About | About | About | Careers | About | About | About
Symbol: STRO
Recent Price: $1.85
Industry: Biotechnology
CEO: Mr. William J. Newell J.D.
Sector: Healthcare
Employees: 304
Address: 111 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 881 6500
Leadership
- John Doe, CEO
- Jane Smith, CTO
- Emily Johnson, Chief Financial Officer
- Michael Brown, President
- Linda Davis, Chairman
- James Wilson, Founder
Last updated: 2024-12-31
XOMA Corporation
Pre-commercial therapeutic candidates
XOMA Corporation operates as a biotechnology royalty aggregator focusing on enhancing human health by acquiring potential future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotech companies. With a portfolio of approximately 70 assets, it focuses on early to mid-stage clinical assets with commercial sales potential.
Symbol: XOMA
Recent Price: $26.09
Industry: Biotechnology
CEO: Mr. Owen P. Hughes Jr.
Sector: Healthcare
Employees: 13
Address: 2200 Powell Street, EmeryVille, CA 94608
Phone: 510 204 7200
Last updated: 2024-12-31
Theriva Biologics, Inc.
SYN-004, SYN-020, VCN-01
Theriva Biologics Inc. is a clinical-stage company developing therapeutics to address diseases with high unmet needs, including SYN-004 for preventing microbiome damage and SYN-020 for treating GI and systemic diseases.
Symbol: TOVX
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Steven A. Shallcross CPA
Sector: Healthcare
Employees: 22
Address: 9605 Medical Center Drive, Rockville, MD 20850
Phone: 301 417 4364
Last updated: 2024-12-31
BioLife Solutions, Inc.
bioproduction tools and services
Bio Life Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services essential for the cell and gene therapy industry globally. The company's offerings include biopreservation media products, automated thawing products, cloud-connected shipping containers, and storage solutions for biologics and pharmaceuticals.
About | Events | Leadership | Leadership | Management | About | About | News | Contact | Contact | Contact | Contact | Contact | About | About | About | About | About
Symbol: BLFS
Recent Price: $26.27
Industry: Medical - Instruments & Supplies
CEO: Mr. Roderick de Greef
Sector: Healthcare
Employees: 409
Address: 3303 Monte Villa Parkway, Bothell, WA 98021
Phone: 425 402 1400
Leadership
- Rod de Greef, Chairman & Chief Executive Officer
- Aby J. Mathew, Ph.D., Executive Vice President and Chief Scientific Officer
- Karen Foster, Chief Quality and Operations Officer
- Troy Wichterman, Chief Financial Officer
- Todd Berard, Chief Marketing Officer
- Garrie Richardson, Chief Revenue Officer
- Sarah Aebersold, Chief Human Resources Officer
- Mike Pallotta, Global VP, Hardware and Electrical Engineering
- Brett Stucker, VP of Cybersecurity and Information Security Officer
- Amy DuRoss,
- Rachel Ellingson,
- Joydeep Goswami, MBA, Ph.D.,
- Tim Moore,
- Joseph Schick, Chairman – Audit Committee
- Andrew Hinson,
- Anthony Davies, Ph.D.,
- Colleen Delaney, M.D., M.Sc.,
- Dayong Gao, Ph.D.,
- Erik Woods, Ph.D., HCLD(ABB),
- Jon Rowley, Ph.D.,
- John McMannis, Ph.D.,
- Jerry E. Cooley, M.D.,
- Jason Acker, MBA, Ph.D.,
- Lizabeth Cardwell, MT (ASCP), MBA, RAC,
- Scott R. Burger, M.D.,
- Shelly Heimfeld, Ph.D.,
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31